New Australian measures to reduce harm from opioids

23 August 2019
australia_credit_depositphotos-1

Australia’s Therapeutic Goods Administration (TGA) is taking action to reduce harm from prescription opioids.

The TGA conducted a public consultation on these medicines last year following a request from the Australian government in light of an increase in hospitalizations and deaths, with these medicines now responsible for far more fatalities than illegal opioids such as heroin.

Following the consultation, new measures are being proposed to ensure that appropriate and safe access is maintained to these drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical